BioVie (NASDAQ:BIVI) Raised to Strong-Buy at Brookline Capital Management

BioVie (NASDAQ:BIVI) was upgraded by stock analysts at Brookline Capital Management to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

BioVie Price Performance

Shares of NASDAQ BIVI opened at $1.06 on Tuesday. The stock has a fifty day moving average price of $1.64 and a 200 day moving average price of $2.14. BioVie has a 1-year low of $0.99 and a 1-year high of $7.50. The company has a market cap of $19.56 million, a PE ratio of -0.11 and a beta of 0.51.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.46) earnings per share for the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BIVI. Millennium Management LLC purchased a new position in BioVie in the fourth quarter worth $245,000. Geode Capital Management LLC raised its position in BioVie by 223.3% in the fourth quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock worth $247,000 after acquiring an additional 85,234 shares in the last quarter. Drive Wealth Management LLC purchased a new position in shares of BioVie in the fourth quarter valued at $120,000. Bank of Montreal Can purchased a new position in shares of BioVie in the fourth quarter valued at $100,000. Finally, Sanders Morris Harris LLC purchased a new position in shares of BioVie in the fourth quarter valued at $85,000. Hedge funds and other institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.